Sugi Predict

Sugi Predict / Targets / CAPNS1

CAPNS1

Calpain small subunit 1 · P04632 · CAPNS1 on Sugi Atlas →

612 patent compounds predicted against CAPNS1, 460 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL4620449 SCHEMBL4620449 1.00 16/20
SCHEMBL4621263 SCHEMBL4621263 1.00 16/20
SCHEMBL4621427 SCHEMBL4621427 1.00 16/20
SCHEMBL4621787 SCHEMBL4621787 1.00 16/20
SCHEMBL4621806 SCHEMBL4621806 1.00 16/20
SCHEMBL4621809 SCHEMBL4621809 1.00 16/20
SCHEMBL4621916 SCHEMBL4621916 1.00 16/20
SCHEMBL4621922 SCHEMBL4621922 1.00 16/20
SCHEMBL4622115 SCHEMBL4622115 1.00 16/20
SCHEMBL4622119 SCHEMBL4622119 1.00 16/20
SCHEMBL4622428 SCHEMBL4622428 1.00 16/20
SCHEMBL4622524 SCHEMBL4622524 1.00 16/20
SCHEMBL4622529 SCHEMBL4622529 1.00 16/20
SCHEMBL4622656 SCHEMBL4622656 1.00 16/20
SCHEMBL4622661 SCHEMBL4622661 1.00 16/20
SCHEMBL4622664 SCHEMBL4622664 1.00 16/20
SCHEMBL4622675 SCHEMBL4622675 1.00 16/20
SCHEMBL4622691 SCHEMBL4622691 1.00 16/20
SCHEMBL4622722 SCHEMBL4622722 1.00 16/20
SCHEMBL4622725 SCHEMBL4622725 1.00 16/20

Clinical trials — most relevant to CAPNS1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit PHASE2/PHASE3WITHDRAWN
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy. PHASE1/PHASE2RECRUITING
Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy EARLY_PHASE1RECRUITING
Clinical and Biochemical Features for the Identification of Dominant Calpainopathies nanUNKNOWN
Effect of Exercise Training on Protein Expression in Skeletal Muscle Tissue After Exercise in Peripheral Arterial Disease nanCOMPLETED
LGMD R1 Natural History Study nanACTIVE_NOT_RECRUITING
High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions nanCOMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
A Multicenter Phenotype-Genotype Analysis of LGMD Patients in China nanENROLLING_BY_INVITATION
Muscle Tissue Bank for Muscular Dystrophy nanCOMPLETED
A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS nanRECRUITING
CoMPaSS-NMD - Computational Models for New Patients Stratification Strategies of HNMD nanENROLLING_BY_INVITATION
Urine Concentration of S100B in Extremely Premature Infants nanCOMPLETED
Evolution of the Functional and Muscular State of Patients With Muscular Dystrophy 2A Belts nanACTIVE_NOT_RECRUITING
Observational Study of Sepsis and Pneumonia to Develop Diagnostic Tests nanUNKNOWN
Genetics of Familial and Sporadic ALS nanCOMPLETED
Relationship of Gestational Age and Urine Concentration of S100B in Preterm and Term Infants in the First Week of Life nanCOMPLETED
Exploring the Genetics of Neuropathic Pain nanRECRUITING
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract nanUNKNOWN
SNAP: Measurement of the Subjective Perception of the Symptom in Hereditary Spastic Paraparesis (HSP) nanCOMPLETED
Effect of Diaphragm Stimulation During Surgery nanCOMPLETED
Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study nanRECRUITING
Role of Sorcin and Annexin A3 in Breast Cancer Patients nanUNKNOWN
Circulating Markers for Ischemic Heart Disease nanRECRUITING
Brain Involvement in Dystrophinopathies Part 2 nanCOMPLETED
Genetic Determinants of Exercise-Induced Muscle Damage (POLYGENDOMUS) nanRECRUITING
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients nanRECRUITING
Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures nanRECRUITING
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CAPNS1 binder may also engage these)

ProteinNameSimilarity
P06813 — 1.000 P06813 →
P13135 — 1.000 P13135 →
O88456 — 1.000 O88456 →
P04574 — 0.997 P04574 →
Q64537 — 0.982 Q64537 →
Q9D7J7 — 0.979 Q9D7J7 →
Q96L46 — 0.979 Q96L46 →
A4IG32 — 0.970 A4IG32 →
P47728 — 0.969 P47728 →
Q3ZBY3 — 0.968 Q3ZBY3 →
Q08331 — 0.967 Q08331 →
B1H2N3 — 0.966 B1H2N3 →
P22676 — 0.965 P22676 →
P07090 — 0.963 P07090 →
D2HZB0 — 0.962 D2HZB0 →
Q6P6Q9 — 0.962 Q6P6Q9 →
Q8VCX5 — 0.960 Q8VCX5 →
Q9BQI0 — 0.959 Q9BQI0 →
Q0IIL1 — 0.959 Q0IIL1 →
Q9BPX6 — 0.959 Q9BPX6 →
Q6P8Y1 — 0.958 Q6P8Y1 →
DCUN1D5 DCN1-like protein 5 0.956 landscape →
Q1RMX9 — 0.956 Q1RMX9 →
Q8WWF8 — 0.955 Q8WWF8 →
Q5RDF9 — 0.955 Q5RDF9 →
Q9ERG2 — 0.954 Q9ERG2 →
P23092 — 0.953 P23092 →
Q5RDI4 — 0.953 Q5RDI4 →
Q17QE5 — 0.952 Q17QE5 →
B1A8Z2 — 0.952 B1A8Z2 →